PARP1 and ovarian carcinoma: In 2018, a PARP inhibitor, Olaparib, received full FDA approval for the treatment of BRCA1/2-mutated breast and ovarian cancer, becoming the first therapy to utilize the principle of synthetic lethality, marking a considerable step forward in the pursuit of effective cancer therapeutics [22].